AmyPore

AmyPore is dedicated to the research, development and valorization of new processes, products, innovative molecules in the pharmaceutical field and aimed at treat or improve the condition of patients with proteinopathies, including neurodegenerative diseases and certain types of diabetes, or prevent the appearance of these diseases. The participation, acquisition, the exploitation or transfer of all patent processes and IP rights related to these activities. Its molecule targeting a mechanism common to Alzheimer's and Parkinson's diseases, AmyP53, has successfully passed all regulatory preclinical tests and will be soon in phase 1 clinical trial in humans. The challenge is to provide patients with a nasal spray for the prevention and treatment of these diseases.

Medicine